Chronic immune stimulation accelerates SIV-induced disease progression

Journal of Medical Primatology

Volumn 30, Issue 5, 2001, Pages 254-259

  Villinger, François ^a,b   Rowe, Thomas ^c   Parekh, Bharat S ^c   Green, Timothy A ^d   Mayne, Ann E ^a   Grimm, Bennett ^a   McClure, Harold M ^b   Lackner, Andrew A ^e   Dailey, Peter J ^f   Ansari, Aftab A ^a   Folks, Thomas M ^c  

^a Department of Pathology and Laboratory Medicine ^*  (United States)

^b EMORY UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BAYER CORPORATION   (United States)

Author keywords

Chronic immune stimulation; HIV; SIV

Indexed keywords

ALLOANTIGEN; KEYHOLE LIMPET HEMOCYANIN; TETANUS TOXOID; VIRUS ANTIBODY;

ACCELERATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CHRONIC DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; EVALUATION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOSTIMULATION; INFECTION CONTROL; INOCULATION; MACACA; NONHUMAN; PERIPHERAL LYMPHOCYTE; PLASMA; PRIORITY JOURNAL; SEROCONVERSION; SIMIAN IMMUNODEFICIENCY VIRUS; SURVIVAL; SYMPTOMATOLOGY; VIRUS INDUCTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; LENTIVIRUS; MACACA; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0035207645     PISSN: 00472565     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0684.2001.d01-57.x     Document Type: Article

References (21)

1. TH1/TH2 subset analysis. I. Establishment of criteria for subset identification in PBMC samples from nonhuman primates
2. Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection
3. Immune activation is a dominant factor in the pathogenesis of African AIDS
4. Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus
5. Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus
6. Immune stimulation may contribute to enhanced progression of SIV induced disease in rhesus macaques
7. Primary acute simian immunodeficiency virus infection of intestinal lymphoid tissue is associated with gastrointestinal dysfunction
8. A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3
9. HIV-1 viraemia and influenza
10. Immune activation and virologic response to immunization in recent HIV type 1 seroconverters
11. Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4 + lymphocyte depletion in rhesus monkeys
12. Interferon-gamma expression in macaque lymph nodes during primary infection with simian immunodeficiency virus
13. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults
14. Human immunodeficiency virus type 1 activation after blood transfusion
15. Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies
16. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
17. Effects of incidental infections and immune activation on disease progression in experimentally feline immunodeficiency virus-infected cats
18. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1
19. Activation of virus replication after vaccination of HIV-1-infected individuals
20. The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults
21. Effects of influenza vaccination in HIV-infected adults: A double-blind, placebo-controlled trial